Design, Development, and Clinical Validation of a Novel Kit for Cell-Free DNA Extraction
<b>Background:</b> Cell-free DNA (cfDNA) has become a cornerstone of liquid biopsy applications, offering promise for early disease detection and monitoring. However, its widespread clinical adoption is limited by variability in pre-analytical processing, especially during isolation. Cur...
Saved in:
| Main Authors: | Ekin Çelik, Hande Güner, Gizem Kayalı, Haktan Bagis Erdem, Taha Bahsi, Hasan Huseyin Kazan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/15/15/1897 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257)
by: Giulia Pasello, et al.
Published: (2025-06-01) -
Unlocking the potential of tumor‐derived DNA in urine for cancer detection: methodological challenges and opportunities
by: Birgit M. M. Wever, et al.
Published: (2025-07-01) -
Liquid Biopsy as a Diagnostic and Monitoring Tool in Glioblastoma
by: Ligia Gabriela Tataranu
Published: (2025-04-01) -
Clinical Utility of ctDNA Analysis in Lung Cancer—A Review
by: Kamil Makar, et al.
Published: (2025-06-01) -
Methylated ARHGAP40 DNA as a potential biomarker for early diagnosis in high-grade ovarian serous cancer
by: Jiaxin Chai, et al.
Published: (2025-07-01)